The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Export 11032 results:
[ Author(Asc)] Title Type Year
Filters: Filter is   [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.. J Clin Gastroenterol. 46(4), 272-84.
Polyzos, S. A., Cundy T., & Mantzoros C. S. (2018).  Juvenile Paget disease.. Metabolism. 80, 15-26.
Polyzos, S. A., Nikolopoulos P., Stogianni A., Romiopoulos I., Katsinelos P., & Kountouras J. (2014).  Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study.. Arq Gastroenterol. 51(3), 261-8.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Alterations in serum thyroid-related constituents after thyroid fine-needle biopsy: a systematic review.. Thyroid. 20(3), 265-71.
Polyzos, S. A., Kang E. Seok, Boutari C., Rhee E-J., & Mantzoros C. S. (2020).  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.. Metabolism. 154203.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Polyzos, S. A., Kechagias S., & Tsochatzis E. A. (2021).  Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.. Aliment Pharmacol Ther.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2015).  Leptin in nonalcoholic fatty liver disease: a narrative review.. Metabolism. 64(1), 60-78.
Polyzos, S. A., & Anastasilakis A. D. (2010).  Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review.. Expert Rev Endocrinol Metab. 5(5), 673-679.
Polyzos, S. A., Kountouras J., & Zavos C. (2011).  Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas.. Int J Clin Pract. 65(3), 373-4.
Polyzos, S. A., Makras P., Anastasilakis A. D., Mintziori G., Kita M., Papatheodorou A., et al. (2017).  Periostin and sclerostin levels in juvenile Paget's disease.. Clin Cases Miner Bone Metab. 14(2), 269-271.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Margouta A., & Mantzoros C. S. (2015).  Association between circulating irisin and homocysteine in patients with nonalcoholic fatty liver disease.. Endocrine. 49(2), 560-2.
Polyzos, S. A., Vachliotis I. D., & Mantzoros C. S. (2023).  Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease.. Metabolism. 147, 155676.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2012).  Sulfated oxysterols as candidates for the treatment of nonalcoholic fatty liver disease.. Metabolism. 61(6), 755-8.
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
Polyzos, S. A., & Katsiki N. (2022).  Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer.. Hormones (Athens).
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., Kountouras J., Goulas A., Papakonstantinou E., & Papaioannidou P. (2020).  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.. Hepatobiliary Surg Nutr. 9(1), 73-76.
Polyzos, S. A., Mathew H., & Mantzoros C. S. (2015).  Irisin: A true, circulating hormone.. Metabolism. 64(12), 1611-8.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2020).  Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.. Metabolism. 104, 154144.
Polyzos, S. A., Anastasilakis A. D., Makras P., & Terpos E. (2011).  Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.. Exp Clin Endocrinol Diabetes. 119(9), 519-24.
Polyzos, S. A., Kountouras J., & Mantzoros C. S. (2019).  Helicobacter pylori infection and nonalcoholic fatty liver disease: Are the four meta-analyses favoring an intriguing association pointing to the right direction?. Metabolism. 96, iii-v.
Polyzos, S. A., & Margioris A. N. (2018).  Sarcopenic obesity.. Hormones (Athens). 17(3), 321-331.
Polyzos, S. A., Goulas A., & Papaioannidou P. (2023).  Tirzepatide for Diabetes and Obesity: A New Window to the Treatment of Non-alcoholic Steatohepatitis. Current Medicinal Chemistry. 30,

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.